The peptide hormone urotensin II (UII) has been highly conserved through the vertebrates from fish to humans. As it was shown to be the endogenous ligand for the mammalian orphan G-protein-coupled receptor GPR14, now renamed the UT receptor, interest in UII physiology has grown. Initial observations of a potent vasoconstrictor effect have been tempered with the subsequent revelation of an endothelium-dependent vasodilator action. These complex and contrasting vascular actions are both species-and vascular bed-specific. UII also plays a role in body fluid regulation in lower vertebrates, and it now appears that this extends to mammals. The kidney is a major source of both circulating and urinary UII. UII is found in both the proximal tubules and collecting ducts; the UT receptor is localized primarily to the renal medulla, with greatest expression in the inner medullary collecting ducts. Infusion in rats produced conflicting results: exogenous UII has been shown to increase glomerular filtration rate (GFR) and excretion of water and sodium, but also to reduce the same variables. Inhibition of UT receptor activity with the antagonist urantide resulted in an increase in GFR, diuresis, and natriuresis, suggesting that endogenous UII exerts a tonic influence on basal renal function. UII may also play a role in renal disease, being elevated in the circulation or urine of patients with renal failure and in experimental models of cardiovascular disease such as the spontaneously hypertensive rat. It remains to be established whether these changes represent an underlying primary cause or a compensatory response.
Urotensin II (UII) was originally identified as one of a number of peptide hormones secreted by the fish caudal neurosecretory system. Synthesized in Dahlgren cells of the caudal spinal cord and released from the urophysis, a neurohemal organ unique to teleost fish, UII has been shown to contract vascular smooth muscle not only in fish but also in mammalian tissues. 1 However, it was not until the discovery by Coulouarn et al. 2 that prepro-UII is expressed in human spinal cord, and peripheral tissues including the kidney, that a role for this peptide hormone was suspected in humans. Shortly after this report, Ames et al. 3 published their landmark paper in the field, which demonstrated that goby UII binds to the human orphan G-protein-coupled receptor GPR14, now designated the UT receptor. Identification of the human form of UII (hUII) 2 revealed that it shares the cyclic hexapeptide sequence, Cys-Phe-Trp-Lys-Tyr-Cys, that is conserved across all species 1 (Figure 1 ) and confers biological activity upon the molecule. 4 Initial attention focused on the vascular actions of UII, not least because of its extremely potent action in nonhuman primates. In vitro, hUII evoked contraction of a wide range of non-human primate arterial vessels; however venous vessels were unresponsive. However, Ames et al. 3 observed less profound responses in rats, with only the thoracic aorta responding to hUII in vitro. In vivo, bolus injection of hUII led to myocardial depression, circulatory collapse, and death in the cynomolgus monkey. 3 Subsequent studies have shown that the vasoactive properties of UII are more complex, with differences both between species and between vascular beds of the same species (reviewed by Douglas et al.; 5 Table 1 ). Over the past few years, UII has emerged as an in vitro spasmogen, up to 100-fold more potent than endothelin I in arteries isolated from rats, humans, and a number of other mammalian species. Its pseudo-irreversible binding properties to the UT receptor have led to the suggestion that UII may function as a chronic regulator of basal vascular tone, rather than a short-term regulator of vascular resistance. 5 UII has also been shown to act as vasodilator: this action was endothelium-dependent, suggesting that vasodilatation is mediated via UT receptors on the endothelium whereas vasoconstriction is mediated via UT receptors on smooth muscle cells. 5 These contrasting effects suggest that UII plays a more complex role in the regulation of vascular tone than initial reports suggested, with UII now emerging as both a paracrine and an endocrine factor.
Despite the growing interest in mammalian UII physiology, one aspect that has received little attention to date is its potential influence on renal function. Evidence that such a role might exist comes from studies in teleost fish, which show that UII contributes to their osmoregulatory physiology. A number of reports have implicated UII in the conservation of water, 6 sodium, and chloride 7 in fish species. The euryhaline flounder, Platichthys flesus, is able to osmoregulate and survive in both seawater and fresh water. When subjected to the hypo-osmotic challenge of a transfer from seawater to fresh water, plasma UII concentration fell rapidly, only returning to pre-transfer levels once the fish had adapted to the new osmotic environment over 72 h later. 6 This is consistent with the notion that UII supports survival in hypertonic media by promoting water retention. 1 UII has also been shown to regulate epithelial sodium transport. Thus, in absorptive tissues of teleost fish, such as urinary bladder and intestine, UII stimulated active sodium and chloride uptake from luminal fluid. Whereas in secretory tissues, such as opercular skin, UII inhibited active sodium and chloride transport. 7 These observations demonstrate that UII can directly affect epithelial ion transport in fish and influence body fluid homeostasis, highlighting that UII may also influence renal function in mammals.
UII AND UT EXPRESSION IN THE KIDNEY
The kidney appears to be a major source of UII synthesis in mammalian species. Prepro-UII mRNA expression has been Figure 1 | The structure of human, rat, and goby UII. All known isoforms share a conserved cyclic hexapeptide sequence, Cys-Phe-Trp-Lys-Tyr-Cys. A disulfide bridge between the two cysteine residues produces a cyclic region which confers biological activity on the molecule. It is this common sequence that is recognized by the UT receptor; hence, fish and mammalian isoforms bind with similar affinity to the receptor. The structure of URP is also shown. This octapeptide, which is identical in humans and rats, also shares the conserved cyclic Cys-Phe-Trp-Lys-Tyr-Cys sequence with UII and is able to bind to the UT receptor. It is notable that vascular beds from the same species show different responses. Furthermore, the same vascular beds in different species differ in their response to UII. This is most striking when comparing the effects of UII in vivo: in the cynomolgus monkey, UII causes profound vasoconstriction, yet in the rat it causes vasodilatation and a reduction systemic blood pressure. Data from Douglas et al., 5 Maguire and Davenport, 31 Camarda et al., 32 and Douglas et al. 33 identified in human, 2,8 primate, and mouse kidneys. 9 Immunoreactive UII expression has been described in human renal blood vessels. 10 This was limited to the arterial vessels, which expressed UII in both endothelial and smooth muscle cells. In the tubule itself, the greatest level of expression was found in the distal and collecting tubules. 10 We observed a somewhat different pattern of UII expression in the rat kidney, with immunostaining present in the proximal tubules, outer, and inner medullary collecting ducts. This is consistent with the observation that UII mRNA expression was significantly higher in the medulla in comparison with the cortex. 11 UII is also present in human 8 and rat 11 urine at concentrations greatly exceeding that in plasma. Human UII clearance equalled or exceeded that of creatinine in normal human subjects, leading to the suggestion that urinary UII is primarily derived from a renal source. 8 Measurement of arteriovenous concentration gradients revealed net secretion of UII into the circulation of the anesthetized sheep by the kidneys, as well as the heart and liver. 12 Thus, renally derived UII may act not only as a local paracrine/autocrine factor in the kidney, but may also play a role as a circulating endocrine.
UT mRNA is expressed in human, 8 monkey, and mouse kidneys. 9 [ 125 I]hUII-binding sites have also been identified in the Sprague-Dawley rat kidney by autoradiography. 13 The majority of binding sites were found in the medulla, with very little cortical binding. This agrees with our observations, by immunohistochemistry, of UT expression in thin ascending limbs and inner medullary collecting ducts, with only occasional immunostaining in glomerular arterioles. 11 We also reported that medullary UT mRNA expression was significantly greater than that in the cortex. 11 Several ligandbinding studies have concluded that UII interacts with a single class of binding site. Competition binding experiments showed that several isoforms of UII (goby, rat, mouse, and porcine A and B) displaced hUII radioligand from mouse and monkey UT receptors transfected into HEK-293 cells with comparable Ki values and Hill coefficients approaching unity. 9 A single class of binding sites for hUII has been described in the rat outer medulla, with an apparent dissociation constant (K d ) of 1.970.9 nM and a maximum binding capacity (B max ) of 408747 amol mm 2 . 13 Taken together, these data suggest that UII may possess renovascular effects, whereas any potential tubular actions are likely to be limited to the loop of Henlé and distal nephron.
The UT receptor has also been shown to bind another peptide, urotensin-related peptide (URP). This octapeptide, identified in humans, mice, and rats, 14 shares the cyclic hexapeptide sequence Cys-Phe-Trp-Lys-Tyr-Cys with UII ( Figure 1 ). Despite the similarity of the mature peptides, the precursor proteins show little sequence homology, consistent with the disparate locations of the human UII and URP genes at 1p36 and 3q29, respectively. In competition binding studies, URP bound to both hUT and rUT receptors with higher affinity than that of hUII (IC 50 in CHO cells expressing hUT receptors was 2.8 nM for URP vs 12 nM for hUII). In vivo, URP induced a hypotensive response in anesthetized rats of similar magnitude to that induced by rUII. Prepro-URP was identified in human kidney, although not in rat kidney; 14 however, we have reported 11 that the rat kidney expresses URP mRNA at levels comparable with that of rUII mRNA. Hence, URP may also activate renal UT receptors and potentially influence renal function in mammals.
RENAL ACTIONS OF UII
There have only been a few reports of the effects of UII on renal function in mammals and these have had conflicting outcomes ( Figure 2 ). We have shown recently 11 that bolus injections of rat UII (rUII) in the low pmol/100 g body weight range produced dose-related reductions in glomerular filtration rate (GFR), which were accompanied by reductions in both urine flow and sodium excretion rates. Preliminary studies in our laboratory show that continuous infusion of rUII over the same concentration range also induced a fall in GFR and an increase in the fractional excretion of sodium (AES Abdel-Razik, RJ Balment, and N Ashton, unpublished observations). However, Ovcharenko et al. 15 saw only modest reductions in GFR and no change in sodium excretion in rats injected with hUII in the low nmol/kg dose range. This contrasts markedly with the observations of Zhang et al. 16 who reported an increase in GFR and a diuresis and natriuresis following continuous intrarenal infusion of hUII in the low pmol/kg range, again in the rat. These differences could reflect dose-related responses or the effect of route of administration. However, Douglas et al. 5 propose another possibility which may account for much of the variability reported here and in the UII literature as a whole. They suggest that most UT receptors are occupied by endogenous UII and, as a result, only a few unoccupied receptors are available to bind exogenous UII. This lack of a spare receptor reserve leads to the variability and low efficacy observed across many studies. One way to overcome the lack of receptor reserve and expose the influence of endogenous UII is through the use of a selective UT receptor antagonist. The most potent UT receptor antagonist available to date is urantide, [Pen 5 , DTrp 7 , Orn 8 ]hU-II(4-11), a derivative of hUII. 17 Administration of urantide in vivo has provided evidence of a heretofore unsuspected role for UII in the regulation of renal function. Continuous infusion of urantide into the rat, at a dose shown to inhibit the vascular actions of exogenous UII, resulted in an increase in GFR, coupled with a diuresis and natriuresis. 11 Fractional excretion of sodium was 44% higher in the urantide-treated group; however, this difference did not reach statistical significance. Thus, it remains unclear whether the natriuresis was due entirely to changes in GFR or if endogenous UII also exerts a direct action on the tubule. Given that UII has been shown to stimulate epithelial sodium transport in fish 7 and that the UT receptor is expressed in the distal nephron of the rat, 11 it is tempting to speculate that UII does have an effect on the tubule itself. Regardless of the site(s) of action, these data strongly suggest that endogenous UII exerts a tonic influence on renal function in the rat. Whether this is the case in humans remains to be determined.
UII IN RENAL DISEASE
A pathophysiological role for UII has been implicated in a number of renal diseases, although it is not yet clear whether it has a causative or protective influence. Patients with renal dysfunction (primarily due to glomerulonephritis or diabetes mellitus) have been reported to have plasma UII concentrations two-to three-fold higher than those of controls. 18 Similarly, patients with diabetic nephropathy have been shown to have elevated plasma and urinary UII concentrations. 19 This was associated with a 64-fold increase in renal UII expression and a 2000-fold increase in UT expression. 20 Plasma UII has also been reported to be elevated in patients with end-stage renal disease. 21 Interestingly, plasma UII concentration was inversely related to sympathetic activity and brain natriuretic peptide (a marker of left ventricular hypertrophy), implying that high plasma UII is associated with relative cardiovascular protection in end-stage renal disease. This was confirmed in a follow-up study in which plasma UII concentration was shown to be inversely related to fatal and non-fatal cardiovascular events in patients with end-stage renal disease, leading the authors to suggest that UII is vasculoprotective in this group. 22 In contrast, chronic heart failure (CHF) patients without reported concurrent renal disease had 43% higher plasma UII concentrations compared with controls. 23 Furthermore, plasma UII was positively correlated with the severity of CHF and both brain natriuretic peptide and big endothelin 1 as markers of left ventricular hypertrophy. One possible explanation for this apparent anomaly is that the study in end-stage renal disease patients documented all cardiovascular events (including angina, myocardial infarction, arrhythmia, heart failure, ischemic events, and stroke) rather than CHF alone, so it is possible that the relationship between plasma UII and cardiovascular events is disease-specific.
There is also evidence from experimental animal models that UII may have some role in cardiovascular disease. CHF is associated with impaired renal function and a reduction in GFR: UII was shown to induce a marked increase in renal blood flow and GFR in a rat model of CHF. 15 This effect was nitric oxide-dependent, suggesting that UII can act as a vasodilator on the renal vasculature. Zhang et al. 16 reached a similar conclusion after demonstrating that hUII induced an endothelium-dependent vasodilatation of the rat renal artery, which was inhibited by N G -nitro-L-arginine methyl ester. This was confirmed using a fluorescent NO indicator, 4,5diaminofluorescein diacetate, which showed that hUII induced NO production in renal artery endothelium.
Changes in UII expression and activity have also been reported in the spontaneously hypertensive rat (SHR). The plasma UII concentration was almost twofold higher in SHR compared with control Wistar-Kyoto (WKY) rats. 11 This is consistent with elevated urinary UII concentrations observed in hypertensive patients. 8 We also observed greater UT mRNA expression in the medulla of SHR, with a similar tendency for UII mRNA expression. 11 Interestingly, URP mRNA expression was reduced by comparison with WKY rats, implying that there is an increase in the UII/URP ratio in the SHR kidney. The vascular response of SHR to UII administration is also enhanced: bolus intravenous injection of hUII produced a greater fall in blood pressure in SHR in comparison with WKY rats. 24 These data suggest that the UII system is upregulated in SHR with established hypertension; however, whether this is cause or effect remains to be determined.
These observations in the SHR raise an important point that must be taken into account when making comparisons across species and even different strains of the same species. Disa et al. 13 noted that the low-affinity binding of [ 125 I]hUII to renal membranes was much lower in both WKY and SHR when compared with Sprague-Dawley rats. We observed similar quantitative differences in UII, URP, and UT mRNA expression between Sprague-Dawley rats and that of WKY and SHR. UT mRNA expression in the cortex of WKY and SHR was eightfold lower and medullary expression was 11fold lower than that in Sprague-Dawley rats. 11 The in vivo response to bolus intravenous UII also differs between rat strains: at 3-10 ng/kg, UII lowered blood pressure in WKY and Sprague-Dawley rats by 10-20%, whereas similar doses reduced blood pressure in Lewis rats by 50%. 13 Thus, caution must be taken when comparing data from different rat strains as it appears that activity of the UII system varies considerably.
UT RECEPTOR ANTAGONISTS
Altered UII expression in disease states has prompted the development of a number of UT receptor antagonists (reviewed by Carotenuto et al. 25 ). Several peptide antagonists have been identified which share a common cyclic region, similar to the conserved sequence of UII (Figure 1 ). This comprises D/LCys-X-D/LTrp-Orn/Lys-Z-Cys, where X is either Phe, [3-pyridyl] Ala, [4-aminophenyl] Ala, or Tyr and Z is either Tyr, Val, or tert-Leu. Of these compounds, urantide is the most potent peptide antagonist developed to date. 17 It acts as a pure antagonist of the rat UT receptor, with a pA 2 of 8.2 in the rat-isolated thoracic aorta bioassy; 17 however, it has been shown to act as an agonist (pEC 50 8.1) in a [Ca 2 þ ]i mobilization assay in CHO cells expressing the hUT receptor. 26 A number of non-peptide compounds have also been developed; these feature a basic amino group and at least two aromatic moieties. The most potent of these is the 4-ureido-quinoline derivative, palosuran (ACT-058362). 27 Palosuran is selective for the human UT receptor, with an IC 50 of 3.6 nM for hUT compared with 1475 nM for rUT. A series of diarlsulfonamide derivatives have been described recently, which appear to be potent antagonists of several forms of the UT receptor. One example, SB-706375, was shown to inhibit [ 125 I]hUII binding to the UT receptor in SJRH30 cells (K i 5.4 nM) as well as rodent, feline, and primate recombinant UT receptors (K i 4.7-20.7 nM). 28 Application of these and other compounds in a variety of disease models has shown that UT antagonism has potential therapeutic benefit. Thus, SB-611812, an arylsulfonamide UT antagonist, has been used to show that UII-induced restenosis can be reduced in rat carotid arteries following balloon angioplasty. 29 Administration of palosuran to streptozotocin-treated rats improved survival, increased insulin, and reduced the progression of renal damage. 30 Similar effects were not seen in preliminary trials in patients with diabetic nephropathy, but further studies are underway to refine the dose regime in an attempt to improve the outcome. The therapeutic potential of UT receptor antagonists has yet to be fully realized, but it seems likely that they will be of clinical use in the treatment of hypertension, heart failure, and renal disease.
CONCLUSIONS
In less than a decade since the discovery that UII is the endogenous ligand for the human orphan receptor GPR14, significant advances have been made in our understanding of the physiology of UII in mammals. UII has emerged as the most potent natural vasoconstrictor peptide, yet it also evokes endothelium-dependent vasodilatation. These effects are both species-and vascular bed-specific, suggesting that although some of the actions of UII have been conserved through evolution, there is also divergence. Rather less is known about UII's actions on the kidney, but recent studies from our lab and others have shown that UII influences GFR and the excretion of water and sodium. A direct effect on the tubular handling of sodium has yet to be demonstrated unequivocally, but circumstantial evidence points to the distal nephron as a potential site of action. The kidney has emerged as one of the main sources of UII in both humans and the rat, where it acts both as a paracrine and a circulating endocrine factor. Many of the biological effects of UII may also be induced by URP, which shares the conserved aminoacid sequence that conveys biological activity. The endogenous stimuli for UII and URP secretion in mammals remain unknown, so it is not clear whether the two peptides are released under similar circumstances. Altered UII and UT expression in renal failure and cardiovascular disease models suggests that UII may play a role in the diseased kidney; whether this role is protective or causal remains to be determined.
